Abstract
We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS). There is evidence that nabiximols oromucosal spray may reduce subjective symptoms of spasticity and that dronabinol is effective against neuropathic pain in patients with MS. The existing treatment system in Denmark is in conformity with the existing data and there is not sufficient evidence to modify it.
MeSH terms
-
Cannabidiol / adverse effects
-
Cannabidiol / therapeutic use
-
Cannabinoids / adverse effects
-
Cannabinoids / therapeutic use*
-
Dronabinol / adverse effects
-
Dronabinol / therapeutic use
-
Drug Combinations
-
Evidence-Based Medicine
-
Humans
-
Medical Marijuana / adverse effects
-
Medical Marijuana / therapeutic use*
-
Multiple Sclerosis / complications
-
Multiple Sclerosis / drug therapy*
-
Muscle Spasticity / drug therapy
-
Muscle Spasticity / etiology
-
Neuralgia / drug therapy
-
Neuralgia / etiology
-
Treatment Outcome
Substances
-
Cannabinoids
-
Drug Combinations
-
Medical Marijuana
-
Cannabidiol
-
Dronabinol